Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

72,269 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Small molecule activation of adaptive gene expression: tilorone or its analogs are novel potent activators of hypoxia inducible factor-1 that provide prophylaxis against stroke and spinal cord injury.
Ratan RR, Siddiq A, Aminova L, Langley B, McConoughey S, Karpisheva K, Lee HH, Carmichael T, Kornblum H, Coppola G, Geschwind DH, Hoke A, Smirnova N, Rink C, Roy S, Sen C, Beattie MS, Hart RP, Grumet M, Sun D, Freeman RS, Semenza GL, Gazaryan I. Ratan RR, et al. Among authors: lee hh. Ann N Y Acad Sci. 2008 Dec;1147:383-94. doi: 10.1196/annals.1427.033. Ann N Y Acad Sci. 2008. PMID: 19076458 Free PMC article.
A large-scale chemical screen for regulators of the arginase 1 promoter identifies the soy isoflavone daidzeinas a clinically approved small molecule that can promote neuronal protection or regeneration via a cAMP-independent pathway.
Ma TC, Campana A, Lange PS, Lee HH, Banerjee K, Bryson JB, Mahishi L, Alam S, Giger RJ, Barnes S, Morris SM Jr, Willis DE, Twiss JL, Filbin MT, Ratan RR. Ma TC, et al. J Neurosci. 2010 Jan 13;30(2):739-48. doi: 10.1523/JNEUROSCI.5266-09.2010. J Neurosci. 2010. PMID: 20071539 Free PMC article.
Superior outcomes and high-risk features with carfilzomib, lenalidomide, and dexamethasone combination therapy for patients with relapsed and refractory multiple myeloma: Results of the multicenter KMMWP2201 study.
Lee JH, Choi J, Min CK, Park SS, Jo JC, Lee YJ, Kim JS, Eom HS, Jung J, Moon JH, Cho HJ, Lee MW, Yoon SS, Byun JM, Lee JH, Lee JJ, Jung SH, Shin HJ, Kim DY, Yi JH, Lee SS, Do YR, Yoon DH, Cho H, Lee WS, Lee HS, Uhm J, Kim HJ, Jang HR, Kim SH, Kim K. Lee JH, et al. Among authors: lee hs. Haematologica. 2024 Jun 6. doi: 10.3324/haematol.2024.285534. Online ahead of print. Haematologica. 2024. PMID: 38841794
Long-term efficacy and safety of tucidinostat in patients with relapsed or refractory peripheral T-cell lymphoma: final analysis of phase IIb results.
Rai S, Kim WS, Ando K, Choi I, Izutsu K, Tsukamoto N, Maruyama D, Tsukasaki K, Kuroda J, Ando J, Hidaka M, Koh Y, Kato H, Uchida T, Yang DH, Ishitsuka K, Ishizawa K, Kim JS, Lee HG, Minami H, Eom HS, Kurosawa M, Lee JH, Lee JS, Lee WS, Nagai H, Shindo T, Yoon DH, Yoshida S, Gillings M, Onogi H, Tobinai K. Rai S, et al. Among authors: lee hg. Haematologica. 2024 Jun 6. doi: 10.3324/haematol.2023.283992. Online ahead of print. Haematologica. 2024. PMID: 38841789
72,269 results
You have reached the last available page of results. Please see the User Guide for more information.